RICH
MCID: RPD005
MIFTS: 38

Rapidly Involuting Congenital Hemangioma (RICH)

Categories: Cardiovascular diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Rapidly Involuting Congenital Hemangioma

MalaCards integrated aliases for Rapidly Involuting Congenital Hemangioma:

Name: Rapidly Involuting Congenital Hemangioma 58
Rich 58

Characteristics:

Orphanet epidemiological data:

58
rapidly involuting congenital hemangioma
Inheritance: Not applicable; Age of onset: Infancy,Neonatal;

Classifications:

Orphanet: 58  
Rare circulatory system diseases
Developmental anomalies during embryogenesis


External Ids:

ICD10 via Orphanet 33 D18.0
UMLS via Orphanet 72 C1275421
Orphanet 58 ORPHA141184

Summaries for Rapidly Involuting Congenital Hemangioma

MalaCards based summary : Rapidly Involuting Congenital Hemangioma, also known as rich, is related to hemangioma and congenital hemangioma. The drugs Insulin aspart and Parathyroid hormone have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and skin, and related phenotypes are telangiectasia of the skin and subcutaneous calcification

Wikipedia : 74 A vascular tumor is a tumor of vascular origin; a soft tissue growth that can be either benign or... more...

Related Diseases for Rapidly Involuting Congenital Hemangioma

Diseases related to Rapidly Involuting Congenital Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 18, show less)
# Related Disease Score Top Affiliating Genes
1 hemangioma 10.8
2 congenital hemangioma 10.8
3 non-involuting congenital hemangioma 10.5
4 arteriovenous malformation 10.2
5 thrombocytopenia 10.2
6 posttransplant acute limbic encephalitis 10.2
7 rare tumor 10.2
8 angioma, tufted 10.1
9 deficiency anemia 10.1
10 telangiectasis 10.1
11 vascular cancer 10.1
12 teratoma 10.1
13 fibrosarcoma 10.1
14 congenital fibrosarcoma 10.1
15 cleft lip 10.1
16 hemangioendothelioma 10.1
17 kaposiform hemangioendothelioma 10.1
18 rare vascular tumor 10.1

Graphical network of the top 20 diseases related to Rapidly Involuting Congenital Hemangioma:



Diseases related to Rapidly Involuting Congenital Hemangioma

Symptoms & Phenotypes for Rapidly Involuting Congenital Hemangioma

Human phenotypes related to Rapidly Involuting Congenital Hemangioma:

58 31 (showing 15, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 telangiectasia of the skin 58 31 frequent (33%) Frequent (79-30%) HP:0100585
2 subcutaneous calcification 58 31 frequent (33%) Frequent (79-30%) HP:0007618
3 midfrontal capillary hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0007466
4 perineal hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0031449
5 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
6 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
7 peripheral arteriovenous fistula 58 31 occasional (7.5%) Occasional (29-5%) HP:0100784
8 prominent superficial veins 58 31 occasional (7.5%) Occasional (29-5%) HP:0001015
9 lipoatrophy 58 31 very rare (1%) Very rare (<4-1%) HP:0100578
10 hepatic hemangioma 58 31 very rare (1%) Very rare (<4-1%) HP:0031207
11 avascular necrosis 31 very rare (1%) HP:0010885
12 aseptic necrosis 58 Very rare (<4-1%)
13 hemangioma 58 Obligate (100%)
14 visceral hemangioma 58 Occasional (29-5%)
15 tufted angioma 58 Excluded (0%)

Drugs & Therapeutics for Rapidly Involuting Congenital Hemangioma

Drugs for Rapidly Involuting Congenital Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 956, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin aspart Approved Phase 4 116094-23-6 16132418
2
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
3
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
4
Lactulose Approved Phase 4 4618-18-2 11333
5
Insulin lispro Approved Phase 4 133107-64-9
6
Insulin glulisine Approved Phase 4 207748-29-6
7
Linagliptin Approved Phase 4 668270-12-0 10096344
8
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
9
leucovorin Approved Phase 4 58-05-9 6006 143
10
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
11
Simvastatin Approved Phase 4 79902-63-9 54454
12
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
13
Magnesium citrate Approved Phase 4 3344-18-1
14
Potassium citrate Approved, Investigational, Vet_approved Phase 4
15 Artichoke Approved Phase 4
16
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
17
Primaquine Approved Phase 4 90-34-6 4908
18
Dimenhydrinate Approved Phase 4 523-87-5 441281
19
Ezetimibe Approved Phase 4 163222-33-1 150311
20
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
21
Palonosetron Approved, Investigational Phase 4 135729-61-2, 135729-56-5, 119904-90-4 148211
22
Pentazocine Approved, Vet_approved Phase 4 359-83-1 441278
23
Metronidazole Approved Phase 4 443-48-1 4173
24
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
25
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
26
Lixisenatide Approved Phase 4 320367-13-3
27
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
28
Histamine Approved, Investigational Phase 4 51-45-6 774
29
Ribavirin Approved Phase 4 36791-04-5 37542
30
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
31
Allopurinol Approved Phase 4 315-30-0 2094
32
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
33
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
34
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
35
Ferrous succinate Approved Phase 4 10030-90-7
36
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
37
Glimepiride Approved Phase 4 93479-97-1 3476
38
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
39
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
40
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
41
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
42
Atorvastatin Approved Phase 4 134523-00-5 60823
43
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
44
Lenograstim Approved, Investigational Phase 4 135968-09-1
45
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
46
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
47
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
48
Probucol Approved, Investigational Phase 4 23288-49-5 4912
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
50
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
51
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
52
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
53
Clarithromycin Approved Phase 4 81103-11-9 84029
54
Ofloxacin Approved Phase 4 82419-36-1 4583
55
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
56
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
57
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
58
Citalopram Approved Phase 4 59729-33-8 2771
59
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
60
Borage oil Approved, Investigational Phase 4
61
Menthol Approved Phase 4 2216-51-5 16666
62
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
63
Glucagon Approved Phase 4 16941-32-5
64
Liraglutide Approved Phase 4 204656-20-2 44147092
65
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
66
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
67
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
68
tannic acid Approved Phase 4 1401-55-4
69
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
70
Kinetin Approved Phase 4 525-79-1 3830
71
Altretamine Approved Phase 4 645-05-6 2123
72
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
73
Ticagrelor Approved Phase 4 274693-27-5 9871419
74
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
75
Fenofibrate Approved Phase 4 49562-28-9 3339
76
Adenosine Approved, Investigational Phase 4 58-61-7 60961
77
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
78
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
79 Garlic Approved, Nutraceutical Phase 4
80
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
81
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
82
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862